Impact of Transcatheter Edge-to-Edge Mitral Valve Repair on Guideline-Directed Medical Therapy Uptitration

Autores da FMUP

• Francisco Pedro Morais Dias De Almeida Sampaio

  Autor

Participantes de fora da FMUP

• Adamo, Marianna
• Tomasoni, Daniela
• Stolz, Lukas
• Stocker, Thomas J.
• Pancaldi, Edoardo
• Koell, Benedikt
• Karam, Nicole
• Besler, Christian
• Giannini, Cristina
• Praz, Fabien
• Ruf, Tobias
• Pechmajou, Louis
• Baldus, Stephan
• Neuss, Michael
• Iliadis, Christos
• Butter, Christian
• Kalbacher, Daniel
• Melica, Bruno
• Lurz, Philipp
• Petronio, Anna S.
• Bardeleben, Ralph Stephan von
• Windecker, Stephan
• Butler, Javed
• Fonarow, Gregg C.
• Hausleiter, Jorg
• Metra, Marco

Unidades de investigação

• Cirurgia e Fisiologia

• Laboratório Associado RISE- Rede de Investigação em Saúde

  

  Investigador

  Fernando Carlos De Landér Schmitt

• RISE-Health

  

  Investigador

  Fernando Carlos De Landér Schmitt

Abstract

BACKGROUND Guideline-directed medical therapy (GDMT) optimization is mandatory before transcatheter edge-to -edge mitral valve repair (M-TEER) in patients with secondary mitral regurgitation (SMR) and heart failure (HF) with reduced ejection fraction (HFrEF). However, the effect of M-TEER on GDMT is unknown. OBJECTIVES The authors sought to evaluate frequency, prognostic implications and predictors of GDMT uptitration after M-TEER in patients with SMR and HFrEF. METHODS This is a retrospective analysis of prospectively collected data from the EuroSMR Registry. The primary events were all-cause death and the composite of all-cause death or HF hospitalization. RESULTS Among the 1,641 EuroSMR patients, 810 had full datasets regarding GDMT and were included in this study. GDMT uptitration occurred in 307 patients (38%) after M-TEER. Proportion of patients receiving angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitors, beta-blockers, and mineral-ocorticoid receptor antagonists was 78%, 89%, and 62% before M-TEER and 84%, 91%, and 66% 6 months after M-TEER (all P < 0.001). Patients with GDMT uptitration had a lower risk of all-cause death (adjusted HR: 0.62; 95% CI: 0.41-0.93; P = 0.020) and of all-cause death or HF hospitalization (adjusted HR: 0.54; 95% CI: 0.38-0.76; P < 0.001) compared with those without. Degree of MR reduction between baseline and 6-month follow-up was an independent predictor of GDMT uptitration after M-TEER (adjusted OR: 1.71; 95% CI: 1.08-2.71; P = 0.022). CONCLUSIONS GDMT uptitration after M-TEER occurred in a considerable proportion of patients with SMR and HFrEF and is independently associated with lower rates for mortality and HF hospitalizations. A greater decrease in MR was associated with increased likelihood for GDMT uptitration. (J Am Coll Cardiol Intv 2023;16:896-905) (c) 2023 by the American College of Cardiology Foundation.

Keywords

• guideline-directed medical; therapy; transcatheter edge-to-edge mitral valve repair; treatment optimization